Articles

Simplified synthesis

Rice University team details new approach for synthesizing aminating agents
Written byKelsey Kaustinen
| 3 min read

HOUSTON—In a discovery expected to streamline and speed synthesis in drug design and manufacturing, the laboratory of László Kürti at Rice University has detailed a simpler method for synthesizing electrophilic aminating agents. These agents are base materials that can add nitrogen atoms to molecules without requiring metals or catalysts that could contaminate the process.

Kürti, a synthetic organic chemist, and his team have created a nitrogen umpolung reagent—a reagent reverses the polarity of nitrogen atoms, which in turn enables them to react differently with other atoms—for synthesizing aminating agents.

“This novel approach represents an operationally simple, scalable and environmentally friendly alternative to transition metal-catalyzed, carbon-nitrogen cross-coupling methods that are currently used to access structurally diverse amines,” Kürti said in a press release.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Published In

Volume 13 - Issue 9 | September 2017

September 2017

September 2017 Issue

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in a white lab coat looking into a microscope in a brightly lit modern laboratory.
Learn how developmental and reproductive toxicology study selection supports regulatory decision-making and generates meaningful nonclinical safety data.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue